Sanofi Stops Supplying Hydroxychloroquine to COVID-19 Patients in Clinical Trials
On the back of mounting concerns about hydroxychloroquine's safety, global pharmaceutical major Sanofi (NASDAQ: SNY) has quit providing it to COVID-19 patients enrolled in its clinical trials for the drug. It has also put a temporary halt on recruiting new subjects for the research.
Hydroxychloroquine, originally designed to treat malaria, was formerly considered a potential treatment for COVID-19, the disease that can result from the SARS-CoV-2 coronavirus. It had some high-level support, most notably from President Donald Trump, who at one point claimed he was regularly taking it.
Image source: Getty Images.
Source Fool.com
